An opportunity to improve the lives of animal and human patients by studying cancers and treatments in both species in parallel
A workshop on Comparative Oncology, hosted by the OHC during #WSAVA2019 in Toronto has resulted in the publication of a manuscript that highlights the value of closer commercial relationships between the human and animal health pharmaceutical and biotech sectors to speed up the development of cancer treatments for both humans and dogs.
OHC Member Dr Chand Khanna from Ethos Veterinary Health and Ethos Discovery, led the workshop with the aim of continuing the development of a new strategy for enhancing cancer drug development using a One Health approach.
Many of the cancers afflicting companion animals also occur in humans, offering the opportunity to improve the lives of animal and human patients by studying cancers and treatments in both species in parallel.
The manuscript has now been published in Annals of Medicine and Clinical Oncology. Entitled Delivering Innovation to Oncology Drug Development through Cancer Drug DISCO (Development Incentive Strategy using Comparative Oncology): Perspectives, Gaps and Solutions’, it outlines new commercial perspectives on the value of closer relationships between the human and animal health pharmaceutical and biotech sectors to deliver a ‘win/win’ for successful cancer drug development in humans and dogs.
Dr Khanna comments:
[blockquote author=”” link=”” target=”_blank”]We hope our recommendations will reposition Comparative Oncology canine trials as integral and parallel to human development and that this move will create opportunities for step-wise iteration and the improvements in the human cancer drug development path that are increasingly necessary.[/blockquote]
Dr Chand Khanna | OHC Member
default
[blockquote author=”” link=”” target=”_blank”]The field of Comparative Oncology as part of cancer drug development stands out as a successful example of the One Health approach to medicine and this new manuscript presents a nuanced and novel strategy to deliver this translational opportunity.[/blockquote] says Dr Michael Lappin, OHC Chair.
Dr Michael Lappin | OHC Chair